Gary Gilkeson, MD
Enriched profileDistinguished University Professor of Medicine/Microbiology and Immunology; Associate Dean for Faculty Affairs and Faculty Development · Medical University of South Carolina (MUSC)
Gary Gilkeson is Distinguished University Professor of Medicine/Microbiology and Immunology; Associate Dean for Faculty Affairs and Faculty Development at Medical University of South Carolina (MUSC). OpenAlex indexes 361 publications with 24,026 citations (h-index 83); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Rheumatology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Gary Gilkeson, MD, is Distinguished University Professor of Medicine/Microbiology and Immunology at Medical University of South Carolina (MUSC). The public record shows 361 publications with 24,026 citations (h-index 83), centered on Systemic Lupus Erythematosus Research, T-cell and B-cell Immunology, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 6 companies, 14 NIH-funded awards (1996–2026).
- Most recent indexed publication: 2025 · Lupus science & medicine
- Top research focus: Systemic Lupus Erythematosus Research
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 255.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Chair Emeritus
Medical-Scientific Advisory Council, Lupus Foundation of America
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lupus.org ↗ - Member
National Board of Directors, Lupus Foundation of America
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lupusnewstoday.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
Sponsor: Medical University of South Carolina
Industry payments
Updated 27 Aug 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- UCB, Inc.Program year20251 payment
- PFIZER INC.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
24.1%Opioid Agonist10.9%Oxycodone Hcl59%Tramadol Hcl22%Hydromorphone Hcl19%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator4.2%Zolpidem Tartrate100%Part D<11 patientsAntiparasitic
22.2%Antimalarial22.2%Hydroxychloroquine Sulfate100%Part D≥31 patientsCancer & immunology
19.2%TNF inhibitor11.6%Enbrel52%Humira(Cf) Pen48%Part D<11 patientsJAK inhibitor4.5%Xeljanz100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
14 NIH research awards on record, funded 1996–2026 per NIH RePORTER. The latest:
- A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)
Medical University of South Carolina
FY2026$1,278,903U01AI184159 - A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)
Medical University of South Carolina
FY2025$1,459,720U01AI184159 - Training Grant in Inflammatory and Fibrosing Diseases
Medical University of South Carolina
FY2025$242,371T32AR050958
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE.
Lupus science & medicine
Clinical Trial2022 - Safety and Efficacy of Mesenchymal Stromal Cells and Other Cellular Therapeutics in Rheumatic Diseases in 2022: A Review of What We Know So Far.
Arthritis & rheumatology (Hoboken, N.J.)
Review2022
Most-cited works
by citation count (OpenAlex)- 01Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis1,128 citations2005
- 02
- 03
- 04
- 05Vitamin D deficiency in systemic lupus erythematosus442 citations2005
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/gary-gilkeson-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/gary-gilkeson-81b360115
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Gary-Gilkeson
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
consultant360.com/podcast/consultant360/lupus-nephritis/gary-gilkeson-md-lupus-and-lupus-nephritis-among-black
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →consultant360.com ↗ - Other
lupus.org/leadership/gary-s-gilkeson-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lupus.org ↗ - Spotify
music.amazon.com/es-co/podcasts/e00baa91-2d65-4ac4-8406-f9a7a4419313/episodes/df34f6fd-f8a6-4b81-a4f3-f5ec90496f03/lupus-science-and-medicine-podcast-mesenchymal-stromal-cells-a-potential-new-sle-treatment-option
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →music.amazon.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.muschealth.org ↗
- BS
Baylor University (summa cum laude)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.muschealth.org ↗ - MD
University of Texas Southwestern Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.muschealth.org ↗ - Internal medicine residency
University of North Carolina at Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.muschealth.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lupusnewstoday.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.muschealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →education.musc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.muschealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →education.musc.edu ↗
Media & interviews
press, podcasts and appearances- Podcast: "Mesenchymal stromal cells: a potential new SLE treatment option?"
Lupus Science and Medicine Podcast (interview on phase I MSC trial for refractory lupus)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →music.amazon.com ↗ - Podcast: "Gary Gilkeson, MD, on Lupus and Lupus Nephritis Among Black Patients"
Rheumatology & Arthritis Learning Network / Consultant360 (discusses SLE and lupus nephritis prevalence among African Americans …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →soundcloud.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Diane Kamen, MD
Medical University of South Carolina (MUSC)
Gerard Silvestri, MD
Medical University of South Carolina (MUSC)
Patrick Flume, MD
Medical University of South Carolina (MUSC)